TNFRSF18 and melanoma: In the tumor setting, mice treated with GITR specific antibodies on the day of B16 melanoma inoculation and for the next seven days showed potent immunity.[4‐6] Moreover, other studies using methylcholanthrene induced tumor cells showed that GITR specific antibodies could be given after tumor injection and still showed generation of anti-tumor immunity.